Canaccord lowered the firm’s price target on Alphatec (ATEC) to $23 from $25 and keeps a Buy rating on the shares. The firm said they posted an uncharacteristic miss in the Q as its EOS business declined 18%year over year. Its surgical business was more in line with expectations, seeing 21% case volume growth and 23% net new surgeon growth but another Q of weak rev/case growth against shifting regional/procedural/biologics mix.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC: